Tang, X., Liu, B., Zhang, C., Tang, W., Liang, S., Xiao, Y., . . . Li, Z. (2021). SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway. Frontiers in Oncology, 11, . https://doi.org/10.3389/fonc.2021.773045
Chicago-referens (17:e uppl.)Tang, Xiaohui, Bohao Liu, Chen Zhang, Wenbin Tang, Shitian Liang, Yadan Xiao, Ruoyu Deng, och Zhuan Li. "SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway." Frontiers in Oncology 11 (2021). https://doi.org/10.3389/fonc.2021.773045.
MLA-referens (9:e uppl.)Tang, Xiaohui, et al. "SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway." Frontiers in Oncology, vol. 11, 2021, https://doi.org/10.3389/fonc.2021.773045.
